Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...

Achondroplasia is a rare genetic disorder of bone growth that causes short-limbed dwarfism. It occurs due to mutations in a single gene called the FGFR3.

Its lead asset is TYRA-300, which targets FGFR3 and will start a phase 2 trial in Achondroplasia. It will also begin another phase 2 trial in Bladder and solid tumors. Among these solid tumors ...